论文部分内容阅读
目的观察辛伐他汀滴丸对冠心病强化调脂治疗的疗效及安全性。方法将91例确诊为冠心病、血清总胆固醇(TC>5.2mmol/L)或低密度脂蛋白胆固醇(LDL-C>3.12mmol/L)。伴或不伴有三酰甘油(TG>1.7mmol/L)的患者随机分为两组。A组(治疗组)46例口服辛伐他汀滴丸40mg/d,8周,B组(对照组)45例口服普伐他汀钠片40mg/d,8周,在服药前、服药后第4、8周分别测定血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)及血糖、血尿素氮、血肌酐、及肌酸激酶(CK)、丙氨酸氨基转移酶(ALT)、天门冬氨酸转移酶(AST)。结果与治疗前相比4、8周TC、LDL-C、TG的下降和HDL-C的升高,两组均有显著性差异(P<0.05)。两组间相比差异无统计学意义(P>0.05)。治疗期间无不良反应发生。结论辛伐他汀滴丸对冠心病强化调脂治疗安全、有效。
Objective To observe the efficacy and safety of simvastatin dripping pills on lipid-lowering therapy with coronary heart disease. Methods Ninety-one patients were diagnosed as coronary heart disease, serum total cholesterol (TC> 5.2mmol / L) or low density lipoprotein cholesterol (LDL-C> 3.12mmol / L). Patients with and without triglycerides (TG> 1.7 mmol / L) were randomized into two groups. A group (treatment group) 46 cases of oral simvastatin 40mg / d, 8 weeks, B group (control group) 45 cases of oral pravastatin sodium tablets 40mg / d, 8 weeks before taking the medication after taking the first 4 , Serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglyceride (TG) and blood glucose, blood urea nitrogen, And creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST). Results Compared with those before treatment, the levels of TC, LDL-C, TG and HDL-C increased at 4 and 8 weeks in both groups (P <0.05). There was no significant difference between the two groups (P> 0.05). No adverse reactions occurred during treatment. Conclusion Simvastatin dropping pills is safe and effective in enhancing lipid-lowering therapy of coronary heart disease.